Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor.
Androgen Receptor Antagonists
/ chemistry
Androgens
/ chemistry
Anilides
/ chemistry
Binding Sites
/ drug effects
Dihydrotestosterone
/ chemistry
Flutamide
/ analogs & derivatives
Humans
Molecular Dynamics Simulation
Nitriles
/ chemistry
Receptors, Androgen
/ metabolism
Testosterone
/ chemistry
Tosyl Compounds
/ chemistry
Journal
The journal of physical chemistry. B
ISSN: 1520-5207
Titre abrégé: J Phys Chem B
Pays: United States
ID NLM: 101157530
Informations de publication
Date de publication:
12 09 2019
12 09 2019
Historique:
pubmed:
23
8
2019
medline:
13
8
2020
entrez:
22
8
2019
Statut:
ppublish
Résumé
Androgen receptor (AR) is a steroid hormone nuclear receptor which upon binding its endogenous androgenic ligands (agonists), testosterone and dihydrotestosterone (DHT), alters gene transcription, producing a diverse range of biological effects. Antiandrogens, such as the pharmaceuticals bicalutamide and hydroxyflutamide, act as agonists in the absence of androgens and as antagonists in their presence or in high concentration. The atomic level mechanism of action by agonists and antagonists of AR is less well characterized. Therefore, in this study, multiple 1 μs molecular dynamics (MD), docking simulations, and perturbation-response analyses were performed to more fully explore the nature of interaction between agonist or antagonist and AR and the conformational changes induced in the AR upon interaction with different ligands. We characterized the mechanism of the ligand entry/exit and found that helix-12 and nearby structural motifs respond dynamically in that process. Modeling showed that the agonist and antagonist/agonist form a hydrogen bond with Thr877/Asn705 and that this interaction is absent for antagonists. Agonist binding to AR increases the mobility of residues at allosteric sites and coactivator binding sites, while antagonist binding decreases mobility at these important sites. A new site was also identified as a potential surface for allosteric binding. These results shed light on the effect of agonists and antagonists on the structure and dynamics of AR.
Identifiants
pubmed: 31431014
doi: 10.1021/acs.jpcb.9b05654
pmc: PMC6742532
mid: NIHMS1047398
doi:
Substances chimiques
AR protein, human
0
Androgen Receptor Antagonists
0
Androgens
0
Anilides
0
Nitriles
0
Receptors, Androgen
0
Tosyl Compounds
0
Dihydrotestosterone
08J2K08A3Y
hydroxyflutamide
31D90UKP5Y
Testosterone
3XMK78S47O
Flutamide
76W6J0943E
bicalutamide
A0Z3NAU9DP
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
7657-7666Subventions
Organisme : NIH HHS
ID : S10 OD023532
Pays : United States
Références
Br J Cancer. 1999 Sep;81(2):242-51
pubmed: 10496349
J Natl Cancer Inst. 2000 Apr 19;92(8):613-21
pubmed: 10772678
Toxicol Sci. 2000 Aug;56(2):389-99
pubmed: 10910998
Proteins. 2000;Suppl 4:63-71
pubmed: 11013401
J Mol Biol. 2000 Nov 10;303(5):797-811
pubmed: 11061976
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5361-6
pubmed: 11959989
J Biol Chem. 2002 Jul 19;277(29):26321-6
pubmed: 12015321
Cancer Res. 2003 Jan 1;63(1):149-53
pubmed: 12517791
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
Proteins. 2004 Nov 15;57(3):433-43
pubmed: 15382234
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6201-6
pubmed: 15833816
Chem Rev. 2005 Sep;105(9):3352-70
pubmed: 16159155
J Comput Chem. 2005 Dec;26(16):1701-18
pubmed: 16211538
J Comput Chem. 2005 Dec;26(16):1781-802
pubmed: 16222654
Chem Biol Drug Des. 2007 Feb;69(2):146-8
pubmed: 17381729
J Biol Chem. 2007 Aug 31;282(35):25801-16
pubmed: 17591767
Mol Endocrinol. 1991 Oct;5(10):1396-404
pubmed: 1775129
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16074-9
pubmed: 17911242
Environ Toxicol Chem. 2008 Feb;27(2):478-88
pubmed: 18348629
J Mol Graph Model. 2008 Nov;27(4):452-8
pubmed: 18805032
PLoS Comput Biol. 2009 Apr;5(4):e1000343
pubmed: 19343225
J Chem Inf Model. 2009 Feb;49(2):377-89
pubmed: 19434839
Mol Endocrinol. 2009 Aug;23(8):1231-41
pubmed: 19443608
Annu Rev Physiol. 2010;72:247-72
pubmed: 20148675
Adv Drug Deliv Rev. 2010 Oct 30;62(13):1218-26
pubmed: 20723571
J Carcinog. 2011;10:20
pubmed: 21886458
DICP. 1990 Jun;24(6):616-23
pubmed: 2193461
Mol Endocrinol. 2012 Jul;26(7):1078-90
pubmed: 22653923
Annu Rev Physiol. 2013;75:201-24
pubmed: 23157556
Cold Spring Harb Perspect Biol. 2013 Mar 01;5(3):a016709
pubmed: 23457262
Pharmacol Ther. 2013 Dec;140(3):223-38
pubmed: 23859952
Oncotarget. 2014 Sep 15;5(17):7217-59
pubmed: 25277175
Acta Pharmacol Sin. 2014 Dec 15;36(1):88-101
pubmed: 25500867
Oncotarget. 2015 Jan 20;6(2):592-603
pubmed: 25595907
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Int J Biol Sci. 2016 Feb 06;12(4):409-26
pubmed: 27019626
Clin Biochem Rev. 2016 Feb;37(1):3-15
pubmed: 27057074
Prostate. 1989;14(2):103-15
pubmed: 2710689
BMC Bioinformatics. 2017 May 25;18(1):271
pubmed: 28545397
Toxicol Sci. 2017 Oct 1;159(2):279-289
pubmed: 28666357
J Am Chem Soc. 2017 Dec 6;139(48):17508-17517
pubmed: 29139290
Curr Mol Biol Rep. 2017;3(4):230-235
pubmed: 29214142
Nat Commun. 2017 Dec 22;8(1):2276
pubmed: 29273709
Am J Clin Exp Urol. 2018 Apr 01;6(2):62-77
pubmed: 29666834
J Chem Theory Comput. 2018 Jul 10;14(7):3859-3869
pubmed: 29768913
Front Pharmacol. 2018 May 15;9:492
pubmed: 29867496
Int J Mol Sci. 2018 Jun 15;19(6):null
pubmed: 29914135
J Chem Inf Model. 2019 Feb 25;59(2):842-857
pubmed: 30658039
N Engl J Med. 1995 May 25;332(21):1393-8
pubmed: 7723794
Proc Natl Acad Sci U S A. 1996 May 28;93(11):5517-21
pubmed: 8643607
EMBO J. 1996 Jul 15;15(14):3667-75
pubmed: 8670870
Urology. 1996 Jul;48(1):157-63
pubmed: 8693644
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Cell. 1998 Dec 23;95(7):927-37
pubmed: 9875847